Season 02: episode 14
In this episode, to showcase the mental health awareness campaigns taking place across Europe and the US throughout the month of May, the GOLD team is joined by two of the pharmaceutical industry’s most unwavering mental health advocates.
Wendy Bartie, Senior Vice President, US Oncology, Bristol Myers Squibb, and Courtney Billington, President, Janssen Neuroscience discern what resources pharma companies should be making available to their employees, what the industry’s role is in supporting patient mental health and how they manage their own mental wellbeing.
There is also news on University of Birmingham’s report ‘Healthy Mum, Healthy Baby, Healthy Future’ and two new education campaigns launched Bristol Myers Squibb, plus a report on pharma advertising trends from tech platform, Veeva Crossix.
A little more on GOLD’s guest…
Wendy Bartie, Senior Vice President, US Oncology, Bristol Myers Squibb, has had a career filled with twists and turns, but her ultimate path has always been a clear one: a commitment to help people and act as a voice for those with unmet needs and unequal access. Following a three-year tenure as a criminal defence litigator in New York and Washington DC, Wendy pivoted to the pharmaceutical industry. Since then, she has worked in almost every commercial area, focusing on oncology where her passion lies. Her father passed away from prostate cancer and her mother became a breast cancer survivor. She boasts expertise in business growth, team leadership, and dynamic marketing development and execution.
Courtney Billington, President, Janssen Neuroscience, began his career as a Quartermaster Officer in the United States Army and retired honourably after serving with the 18th Airborne Corps at Fort Campbell, KY, and in Operation Desert Storm in 1991 during the Persian Gulf War. Courtney went on to earn a B.Sc in general engineering management from the U.S. Military Academy at West Point. But it’s at Johnson & Johnson that he’s been for the last 30 years. In his current role, Courtney leads the Neuroscience business in providing innovative treatments and services for patients living with serious mental illness and neurological disorders, with a focus on schizophrenia, multiple sclerosis and forms of challenging-to-treat depression.
